Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Aleskandarany, Mohammed A ^a,b   Green, Andrew R ^a   Benhasouna, Ahmed A ^a   Barros, Fabricio F ^a   Neal, Keith ^a   Reis Filho, Jorge S ^c   Ellis, Ian O ^a   Rakha, Emad A ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CELL PROLIFERATION; FEMALE; HUMAN; LABELING INDEX; MAJOR CLINICAL STUDY; MITOSIS; SCORING SYSTEM; ADOLESCENT; BIOLOGICAL MODEL; BREAST TUMOR; CANCER INVASION; CLASSIFICATION; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MITOSIS INDEX; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; MITOTIC INDEX; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 84855464719     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3084     Document Type: Article

References (37)

1. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 2001, 30:27-35.
2. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65. 10.1186/bcr2124, 2575538, 18662380.
3. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-80.
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-26. 10.1056/NEJMoa041588, 15591335.
5. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-72. 10.1093/jnci/djj052, 16478745.
6. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-301. 10.1158/0008-5472.CAN-05-4414, 17079448.
7. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006, 8:216. 10.1186/bcr1618, 1797032, 17164010.
8. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008, 26:3153-8. 10.1200/JCO.2007.15.5986, 18490649.
9. Johnson HA, Bond VP. A method of labeling tissues with tritiated thymidine in vitro and its use in comparing rates of cell proliferation in duct epithelium, fibroadenoma, and carcinoma of human breast. Cancer 1961, 14:639-43. 10.1002/1097-0142(199005/06)14:3<639::AID-CNCR2820140327>3.0.CO;2-C, 13790278.
10. van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004, 57:675-81. 10.1136/jcp.2003.010777, 1770351, 15220356.
11. Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000, 18:2059-69.
12. Medri L, Volpi A, Nanni O, Vecci AM, Mangia A, Schittulli F, Padovani F, Giunchi DC, Zito A, Amadori D, Paradiso A, Silvestrini R. Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol 2003, 16:1067-75. 10.1097/01.MP.0000093625.20366.9D, 14614045.
13. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16:1723-39. 10.1093/annonc/mdi352, 15980158.
14. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS, . International Breast Cancer Study Group Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008, 100:207-12. 10.1093/jnci/djm289, 18230798, International Breast Cancer Study Group.
15. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991, 138:867-73. 1886092, 2012175.
16. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-50. 10.1093/jnci/djp082, 2684553, 19436038.
17. Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes JF. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score: results from TransATAC. Cancer Res 2009, (Suppl 24):74.
18. Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009, 11:R23. 10.1186/bcr2249, 2688952, 19405945.
19. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11:339-49. 10.1016/S1470-2045(10)70008-5, 20181526.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-10. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
21. Ellis IO, , . Programmes NHSCS, Royal College of Pathologists, The Science C Pathology Reporting of Breast Disease: a Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of the Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. 2005, London: NHS Cancer Screening Programmes, Royal College of Pathologists, Programmes NHSCS, Royal College of Pathologists, The Science C.
22. Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG, Paish EC, Macmillan RD, Chan S, Ahmed SI, Ellis IO. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer 2010, 126:1761-9.
23. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-10. 10.1158/1078-0432.CCR-08-2132, 19318481.
24. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-8. 10.1200/JCO.2007.12.2747, 17876012.
25. Garcia-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 2010, 56:472-80. 10.1111/j.1365-2559.2010.03503.x, 2855864, 20459554.
26. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 2007, 26:1507-16. 10.1038/sj.onc.1209920, 16936776.
27. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value to triple-negative phenotype. Clin Cancer Res 2008, 14:1368-76. 10.1158/1078-0432.CCR-07-1658, 18316557.
28. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-9. 10.1158/1078-0432.CCR-04-0713, 15534099.
29. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002, 94:2151-9. 10.1002/cncr.10458, 12001111.
30. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001, 85:1106-12. 10.1054/bjoc.2001.2048, 2375158, 11710821.
31. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-502. 10.1001/jama.295.21.2492, 16757721.
32. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:R67. 10.1186/bcr2128, 2575540, 18681955.
33. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006, 48:674-82. 10.1111/j.1365-2559.2006.02402.x, 16681683.
34. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R. Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 2006, 59:138-45. 10.1136/jcp.2004.025551, 1860326, 16443727.
35. Bergers E, Jannink I, van Diest PI, Cuesta MA, Meyer S, van Mourik JC, Baak JP. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol 1997, 28:95-100. 10.1016/S0046-8177(97)90286-0, 9013839.
36. Start RD, Cross SS, Smith JH. Assessment of specimen fixation in a surgical pathology service. J Clin Pathol 1992, 45:546-7. 10.1136/jcp.45.6.546, 495239, 1306049.
37. Kwok TC, Rakha EA, Lee AH, Grainge M, Green AR, Ellis IO, Powe DG. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. Histopathology 2010, 57:212-19. 10.1111/j.1365-2559.2010.03620.x, 20716163.